Insulin-degrading enzyme higher in subjects with metabolic syndrome

Y. Sofer*, Y. Nash, E. Osher, O. Fursht, G. Goldsmith, L. Nahary, S. Shaklai, K. M. Tordjman, M. Serebro, E. B. Touati, M. Yacobi Bach, Y. Marcus, B. Tal, J. Sack, G. Shefer, M. Margaliot, N. Landis, I. Goldiner, W. Abu Ahmad, N. SternI. Benhar, D. Frenkel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Metabolic syndrome (MS) is comprised of a cluster of abnormalities in glucose, lipid, and vascular homeostasis, which is most commonly linked to abdominal obesity. MS heralds increased risk for development of diabetes and is linked to impairment in insulin signaling. Insulin-degrading enzyme (IDE) is one of the mechanisms through which insulin blood levels are maintained. It has been previously suggested that controlling IDE levels could provide yet another potential therapeutic approach in diabetes. Here we aim to investigate whether changes in serum IDE levels correlate with the severity of MS. Using a highly sensitive ELISA assay of active IDE in human serum, we found a strong correlation between circulating IDE levels and circulating levels of triglycerides, insulin, and c-peptide and an inverse correlation with HDL cholesterol (HDLc). Serum IDE levels were higher in MS subjects than in control subjects. Hence, circulating IDE may serve as a tool to identify subjects with abnormal insulin metabolism, possibly those with MS that are at risk to develop diabetes.

Original languageEnglish
Pages (from-to)357-364
Number of pages8
Issue number2
StatePublished - Feb 2021


FundersFunder number
Shoham foundation


    • Insulin Degradation
    • Insulin Resistance
    • Metabolic Syndrome
    • Prediabetes


    Dive into the research topics of 'Insulin-degrading enzyme higher in subjects with metabolic syndrome'. Together they form a unique fingerprint.

    Cite this